[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
스폰서배너광고 안내  배너1
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
사진없음
박옥이 (Ogyi Park) 저자 이메일 보기
NIAAA/NIH, Johns Hopkins University School of Medicine
조회 963  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells
Yumin Oh1,2,10, Ogyi Park1,2,3,10, Magdalena Swierczewska1,2,10, James P. Hamilton,4 Jong-Sung Park1,2, Tae Hyung Kim1,2, Sung-Mook Lim5, Hana Eom5, Dong Gyu Jo5, Choong-Eun Lee6, Raouf Kechrid3, Panagiotis Mastorakos2, Clark Zhang2, Sei Kwang Hahn7, Ok-Cheol Jeon8, Youngro Byun8, Kwangmeyung Kim9, Justin Hanes2, Kang Choon Lee5, Martin G. Pomper1, Bin Gao3,* and Seulki Lee1,2,*

1The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 3Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA 4Divison of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 5College of Pharmacy, Sungkyunkwan University, Suwon, Korea 6Department of Biological Science, Sungkyunkwan University, Suwon, Korea 7Department of Materials Science and Engineering, Pohang University of Science and Technology, Pohang, Korea 8College of Pharmacy, Seoul National University, Seoul, Korea 9Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea 10These authors contributed equally to this work.

* Correspondence authors: Bin Gao, M.D., Ph.D., Laboratory of Liver Diseases, NIAAA/NIH, 5625 Fishers Lane, Bethesda, MD 20892. and Seulki Lee, Ph.D. The Russell H. Morgan Department of Radiology and Radiological Sciences, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University, School of Medicine, Baltimore, MD 21231. 

Abstract
Liver fibrosis is a common outcome of chronic liver disease and leads to liver cirrhosis and hepatocellular carcinoma. No FDA-approved targeted anti-fibrotic therapy exists. Activated hepatic stellate cells (aHSCs) are the major cell types responsible for liver fibrosis; therefore, eradication of aHSCs, while preserving quiescent HSCs and other normal cells, is a logical strategy to stop and/or reverse liver fibrogenesis/fibrosis. However, there are no effective approaches to specifically deplete aHSCs during fibrosis without systemic toxicity. aHSCs are associated with elevated expression of death receptors (DRs) and become sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death. Treatment with recombinant TRAIL could be a potential strategy to ameliorate liver fibrosis; however, the therapeutic application of recombinant TRAIL is halted due to its very short half-life. To overcome this problem, we previously generated PEGylated TRAIL (TRAILPEG) that has a much longer half-life in rodents than native-type TRAIL. Here, we demonstrate that intravenous TRAILPEG has a markedly extended half-life over native-type TRAIL in non-human primates and has no toxicity in primary human hepatocytes. Intravenous injection of TRAILPEG directly induces apoptosis of aHSCs in vivo and ameliorates carbon tetrachloride-induced fibrosis/cirrhosis in rats by simultaneously down-regulating multiple key fibrotic markers that are associated with aHSCs. In conclusion, TRAIL-based therapies could serve as new therapeutics for liver fibrosis/cirrhosis and possibly other fibrotic diseases. This article is protected by copyright. All rights reserved.

Keywords: apoptosis, cirrhosis, death receptors, fibrosis, hepatic stellate cells, TRAIL
논문정보
- 형식: Research article
- 게재일: 2015년 12월 (BRIC 등록일 2015-12-29)
- 연구진: 국내+국외 연구진
- 분야: Medicine
Leucyl-tRNA synthetase 1에 의한 포도당 의존적 류신 감지 및 대사 조절[Science]
윤이나
발표: 윤이나 (서울대학교)
일자: 2020년 2월 28일 (금) 오후 02시 (한국시간)
언어: 한국어
참석자 접수신청하기
NK세포에 의한 손상된 말초신경 제거 기전 – 새로운 만성통증 치료법[ Cell ]
오석배
발표: 오석배 (서울대학교)
일자: 2020년 3월 5일 (목) 오전 10시 (한국시간)
언어: 한국어
참석자 접수신청하기
ATAD5가 복제 스트레스 상황에서 복제를 재개하는 세포생물학적 기작[ Nat. Commun.]
박수형
발표: 박수형 (기초과학연구원)
일자: 2020년 3월 12일 (목) 오후 03시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
등록
 
목록
라이브셀인스트루먼트
관련링크
박옥이 님 전체논문보기 >
관련인물
기성환 (조선대학교)
오유민 (Johns Hopkins U...)
이슬기 (Johns Hopkins U...)
관련분야 논문보기
Medicine

외부링크
Google (by Ogyi Park)
Pubmed (by Ogyi Park)
프리미엄 Bio일정 Bio일정 프리미엄 안내
[BRIC Webinar]Leucyl-tRNA synthetase 1에 의한 포도당 의존적 류신 감지 및 대사 조절[Science]
[대전] Synthego CRISPR Genome Editing User Seminar에 초대합니다.
[대전] Synthego CRISPR Genome Editing User Seminar에 초대합니다.
날짜: 2020.03.05
장소: 한국생명공학연구원 본관동 대회의실(B)
[고용부 재직자 무료과정]의료기기 GMP의 이해 과정
[고용부 재직자 무료과정]의료기기 GMP의 이해 과정
날짜: 2020.03.09~11
장소: 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실
2020 서경배과학재단 신진과학자 연구지원 프로그램
2020 서경배과학재단 신진과학자 연구지원 프로그램
날짜: 2020.03.31
주관: 서경배과학재단
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
에펜도르프코리아